For research and educational purposes only. Not medical advice.
PNC-28 Reference
Educational, not medical advice reference for PNC-28: Immune; regulatory status, evidence posture, source review, and schedule notes. Also known as p53-deriv…
Reference summary
Older studies describe transformed-cell cytotoxicity and pancreatic-cancer-cell necrosis models. Human clinical efficacy data are absent.
- Categories
- Immune
- Aliases
- p53-derived penetratin peptide, PNC28, Anticancer research peptide
- Evidence posture
- preclinical — Fringe anticancer peptide. No human clinical efficacy evidence; not a treatment protocol or substitute for oncology care.
- Regulatory status
- No FDA-approved PNC-28 drug label. PNC-28 is not an approved cancer treatment. Published work is preclinical and mechanistic.
- Content review status
- research reference